The E3 ubiquitin ligase Cbl-b acts as a key regulator of T cell activation and peripheral tolerance. Cbl-b deficiency uncouples the requirement of CD28 costimulation for T cell activation and exhibits resistance to T cell anergy and tolerance. Cbl-bmice are highly susceptible to autoimmune diseases. Conversely, they mount a robust antitumor response resulting in spontaneous tumor rejection. Therefore, modulation of Cbl-b might provide a unique opportunity for immunotherapeutic strategies for inflammatory disorders, including autoimmunity and cancer.
|Original language||English (US)|
|Title of host publication||Trends in Stem Cell Proliferation and Cancer Research|
|Number of pages||9|
|State||Published - Jan 1 2013|
- Regulatory T cells
ASJC Scopus subject areas